Business
Cocaine announcement by marijuana company Adastra leads to lawsuit
Canada-based Adastra Holdings faces a proposed class action lawsuit from a shareholder who alleges the marijuana company made “misleading statements about (its) ability to legally sell cocaine.”
The notice of civil claim filed March 9 in the Supreme Court of British Columbia also names Adastra CEO Michael Forbes as a defendant.
Forbes did not provide comment in time for MJBizDaily’s deadline.
Adastra, formerly known as Phyto Extractions and based in Langley, British Columbia, denies the claim’s allegations.
On Feb. 22, Adastra announced it had received an amendment to its Controlled Drug and Substances Dealer’s License to “legally possess, produce, sell and distribute” cocaine.
As MJBizDaily previously reported, the amended license did not allow Adastra to sell cocaine to the general public.
A dealer’s license allows Canadian organizations to legally possess and work with controlled substances.
Adastra’s February news release didn’t explicitly state the company planned to sell cocaine to the public, nor did Adastra’s material-change filing regarding the license amendment.
However, a statement in the news release by CEO Forbes said Adastra would “evaluate how the commercialization of this substance fits in with our business model at Adastra in an effort to position ourselves to support the demand for a safe supply of cocaine.”
British Columbia recently decriminalized possession of certain illegal drugs, including cocaine, as part of a pilot project with authorization from Canada’s federal government.
The legal claim also highlighted language used by Adastra in 2022, when the company filed a material-change report about receiving its dealer’s license to possess and process psilocybin and psilocin.
In that filing, Adastra specified it could transfer the psychedelic substances “to other companies who hold a valid Dealer’s License.”
Similar language does not appear in Adastra’s disclosure about the license amendment for cocaine or in the company’s February news release.
Adastra’s share price spiked after its cocaine announcement, and the issue briefly became political news in Canada.
B.C. Premier David Eby said he was “astonished” by Adastra’s announcement, and Canadian Prime Minister Justin Trudeau also expressed surprise.
Adastra formally retracted its February news release on Friday, March 3, clarifying that it could not sell cocaine to the public and “is only permitted to sell to other licensed dealers who have cocaine listed on their license” – pharmacists or hospitals, for example.
At the time, Adastra stock (XTRX) was trading on the Canadian Securities Exchange (CSE) at 1.38 Canadian dollars ($1) per share, according to the court filing.
When the CSE reopened on Monday, March 6, the price of Adastra shares fell significantly.
Plaintiff Trevor Silverwood bought 220 Adastra shares on March 3 at CA$1.45 per share.
“This action seeks to hold the defendants responsible for their inaccurate and careless representations, and to compensate individuals who purchased shares of Adastra Holdings Ltd. at artificially inflated share prices after the defendants’ misleading statements about Adastra’s ability to legally sell cocaine,” the court filing noted.
Silverwood is represented by law firm Slater Vecchio, which declined to comment to MJBizDaily.
In a news release, Adastra said it “denies the allegations in the claim and specifically that the (Feb. 22) press release was misleading and intends to vigorously defend against these allegations should the class action be certified.”
Source: https://mjbizdaily.com/cocaine-announcement-by-marijuana-company-adastra-leads-to-lawsuit/
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy